MIND C.T.I. Ltd. (NASDAQ: MNDO) put two Nasdaq deficiency letters into the same release as its second quarter results on August 6, 2026. One concerns the minimum bid price of its ordinary shares. The other concerns the composition of its audit committee, and follows the resignation of a director who has moved into an executive role at the company.

The bid price letter arrived on June 23, 2026. Nasdaq told the company it was no longer in compliance with the minimum bid price requirement for continued listing and gave it a compliance period of 180 calendar days, to December 21, 2026. MIND said that if it does not regain compliance in that window it may be eligible for an additional period, and that if Nasdaq staff conclude the deficiency cannot be cured, the ordinary shares will be subject to delisting. The company said it will monitor the closing bid price and consider available options, without naming any.

The audit committee letter arrived on August 3, 2026, after Orly Sorokin resigned from the board and the audit committee. Nasdaq cited Listing Rule 5605©(2). Under Listing Rule 5605©(4) the company has a cure period running to the earlier of its next annual shareholders meeting or August 1, 2027, and must submit documentation including biographies of any new directors. MIND said it intends to fix the deficiency at an annual general meeting in May 2027. Both letters leave the listing untouched for now, and the shares continue to trade under the symbol MNDO.

What the rules behind the letters actually say

The bid price standard is set out in the Nasdaq rulebook and described in Securities and Exchange Commission orders approving changes to it. A failure occurs when a security has a closing bid price below $1.00 for 30 consecutive business days, under Nasdaq Rule 5810©(3)(A). Compliance is regained by meeting the standard for a minimum of 10 consecutive business days during the compliance period, unless staff extend that window. For a primary equity security on the Nasdaq Global or Global Select Markets the requirement sits in Rule 5450(a)(1).

The second compliance period MIND refers to is not automatic and is not open to every listing tier. In the SEC order approving Nasdaq’s 2025 changes to Rules 5810 and 5815, the Commission set out that a company listed on, or that transfers to, the Nasdaq Capital Market may be provided with a second 180-day compliance period, subject to meeting the market value of publicly held shares requirement and all other initial listing standards for that market except bid price, and to notifying Nasdaq of its intent to cure. Nasdaq stated in that filing that it provides a second period only where the company has said it intends to cure by effecting a reverse stock split.

A company that is not eligible, or that fails in the second period, receives a delisting determination appealable to a Hearings Panel, which may grant up to a further 180 days. Nasdaq’s own arithmetic in the filing is that a company can be continuously deficient for more than 360 days but not more than 540 days.

The audit committee cure period has a federal source as well as an exchange one. Rule 10A-3 under the Exchange Act requires listing standards to give issuers an opportunity to cure defects, and permits exchange rules to let a member who ceases to be independent for reasons outside that member’s reasonable control remain on the committee until the earlier of the next annual shareholders meeting or one year from the triggering event. The Nasdaq cure period MIND describes tracks that structure.

Where the audit committee stood before the resignation

MIND’s annual report on Form 20-F records that under the Israeli Companies Law the board must appoint an audit committee comprised of at least three directors, and lists the committee as Joseph Tenne, its chairman, Itay Barzilay and Orly Sorokin. The same filing states that all members of the audit committee are independent directors under the Nasdaq rules and meet the additional qualifications for audit committee and compensation committee membership. The committee also serves as the compensation committee.

The quarter underneath the letters

Second quarter revenues were $4.6 million against $4.8 million a year earlier, with the decline attributed mainly to the messaging segment. Operating income was $0.7 million, or 15% of revenues, against $0.3 million and 6%, which the company put down to a different revenue mix with improved margins. Net income was $0.8 million, or $0.04 per share, against $0.5 million and $0.02. Cash flow from operating activities was $0.1 million against $0.9 million.

For the six months, revenues were $9.7 million, the same as a year earlier, with operating income of $1.6 million, or 17% of revenues, against $0.6 million and 7% in a period that included an allowance for credit loss on a specific customer and acquisition related costs. Net income was $1.6 million, or $0.08 per share. Operating cash flow for the half was $0.7 million against $1.6 million.

Cash, including short-term deposits and marketable securities, was $13.5 million on June 30, 2026, against $11.4 million a year earlier. The company paid the remaining approximately $261 thousand of the Aurenz acquisition consideration in the second quarter, after an initial $1.7 million in the first quarter of 2025, and absorbed roughly $288 thousand of withholding tax on an intragroup dividend that it expects to recover. Under the repurchase plan authorised on November 12, 2025 for up to $2.4 million, MIND had bought 617 thousand shares for approximately $674 thousand by June 30, 2026, of which $350 thousand fell in the quarter.

Revenue by region in the quarter was Europe 60%, including the German messaging business at 32%, the Americas at 30% and the rest of the world at 10%. By product, customer care and billing software was $2.4 million or 52% of revenues, enterprise messaging and payment solutions $1.5 million or 32%, and unified communications analytics $0.7 million or 16%. Maintenance and additional services accounted for $4.3 million, or 94% of revenues, with licences at $0.3 million.

Interim Chief Executive Monica Iancu said the immediate priority is “to offset the anticipated mid-term revenue decline by accelerating commercial efforts”, and named Sorokin as the newly appointed Chief Business Officer.

Analysis: two clocks, and only one of them is inside the company’s control

The audit committee problem has a mechanical fix and a known deadline. Israeli law requires three members, the committee had three, one left, and the cure is the appointment of a qualifying independent director. The company has said it will do that at a general meeting in May 2027, which falls inside the August 1, 2027 outer limit. The point that follows from the disclosure is not the timing but the reason: the departing member became an executive of the company, so a director who counted toward independence is now management. That reduces the pool of sitting independent directors rather than merely creating a vacancy.

The bid price problem is different in kind. The remedy is a share price, and the disclosure gives no evidence about how the company intends to produce one. The rulebook shows why the eligibility question matters more than the December 21, 2026 date. The second 180-day period is available on the Nasdaq Capital Market, and MIND is described in its own release as NasdaqGM. On the Global Market the path to a second period runs through a transfer of listing tier, and Nasdaq’s stated practice is to grant a second period where a company has notified it of an intent to cure by reverse stock split. MIND’s release says only that it will consider available options.

The operating figures move in the other direction. Half year revenue was flat, operating margin roughly doubled, net income rose and the cash position is higher than a year ago, and the company was buying back shares while the bid price deficiency ran. What the release does describe is an anticipated mid-term revenue decline in the interim chief executive’s own words, and a messaging segment that is already the stated cause of the quarterly revenue drop while representing 32% of quarterly revenue.

What a careful reader would check next is narrow and dated. Whether MIND applies to transfer to the Nasdaq Capital Market before December 21, 2026 will show which compliance route it is taking. Whether a new independent director is named before the May 2027 meeting will show whether the audit committee fix is a formality or a search. And the third quarter revenue split will show whether the messaging decline the company flagged is a single quarter or the mid-term trend it warned about.